Test Code MCRSP MayoComplete Targeted RNA Sequencing Panel, Next-Generation Sequencing, Tumor
Ordering Guidance
Multiple oncology (cancer) gene panels are available. For more information see Hematology, Oncology, and Hereditary Test Selection Guide.
Necessary Information
A pathology report (final or preliminary), at minimum containing the following information, must accompany specimen for testing to be performed:
1. Patient name
2. Block number-must be on all blocks, slides, and paperwork (can be handwritten on the paperwork)
3. Tissue collection date
4. Source of the tissue
5. Diagnosis, potential diagnosis, or differential diagnoses
Specimen Required
This assay requires at least 10% tumor nuclei.
-Preferred amount of tumor area with sufficient percent tumor nuclei: tissue 144 mm(2)
-Minimum amount of tumor area: tissue 36 mm(2)
-These amounts are cumulative over up to 10 unstained slides and must have adequate percent tumor nuclei.
-Tissue fixation: 10% neutral buffered formalin, not decalcified
-For specimen preparation guidance, see Tissue Requirements for Solid Tumor Next-Generation Sequencing. In this document, the sizes are given as 4 mm x 4 mm x 10 slides as preferred: approximate/equivalent to 144 mm(2) and the minimum as 3 mm x 1 mm x 10 slides: approximate/equivalent to 36 mm(2).
Preferred: Submit 3, if available, or 2 of the following specimens.
Acceptable: Submit at least one of the following specimens.
Specimen Type: Tissue block
Collection Instructions: Submit a formalin-fixed, paraffin-embedded tissue block with acceptable amount of tumor tissue.
Specimen Type: Tissue slides
Slides: 1 Hematoxylin and eosin-stained and 10 unstained
Collection Instructions:
Submit the followings slides:
1 Slide stained with hematoxylin and eosin
AND
10 Unstained, nonbaked slides with 5-micron thick sections of the tumor tissue.
Note: The total amount of required tumor nuclei can be obtained by scraping up to 10 slides from the same block.
Additional Information: Unused unstained slides will not be returned.
Specimen Type: Cytology slides (direct smears or ThinPrep)
Slides: 1 to 3 Slides
Collection Instructions: Submit 1 to 3 slides stained and coverslipped with a total of 5000 nucleated cells (preferred) or at least 3000 nucleated cells (minimum).
Note: Glass coverslips are preferred; plastic coverslips are acceptable but will result in longer turnaround times.
Additional Information: Cytology slides will not be returned. An image of the slides will be stored per regulatory requirements.
Useful For
Primarily for identifying gene fusions that help in the diagnosis of solid tumors
Secondarily, for identifying gene fusions that have therapeutic or prognostic significance
Genetics Test Information
This test uses next-generation sequencing to evaluate 1445 genes for the presence of somatic gene fusions, known abnormal transcript variants in the MET and EGFR genes, and BCOR exon 15 internal tandem duplications. See Targeted Fusion Genes for MayoComplete Targeted RNAseq Panel for details regarding the targeted gene regions evaluated by this test.
This test is performed to evaluate for somatic gene fusions within solid tumor samples. It does not assess for germline alterations.
Additional Tests
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| SLIRV | Slide Review in MG | No, (Bill Only) | Yes |
Testing Algorithm
When this test is ordered, slide review will always be performed at an additional charge.
Special Instructions
Reporting Name
MayoComplete Targeted RNAseq PanelSpecimen Type
VariesSpecimen Minimum Volume
See Specimen Required
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Varies | Ambient (preferred) | |
| Refrigerated | ||
Reject Due To
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.Reference Values
An interpretive report will be provided.
Supportive Data
Performance Characteristics:
Validation studies demonstrated that concordance between this test, and the reference method, for detection of gene fusions, BCOR in-tandem duplications, and splice variants within MET and EGFR is 96.6% (256/265). No gene fusions were detected in 14 normal tissues, and no gene fusions were detected in the negative control sample (100% specificity).
To ensure that this assay detects fusions based on the established sensitivity, this test will be performed on cases that are estimated by a pathologist to have at least 10% tumor cells.
Day(s) Performed
Monday through Friday
Report Available
12 to 20 daysSpecimen Retention Time
Tissue blocks: Unused portions of blocks will be returned; Tissue slides: Unused slides are stored for at least 5 years; Extracted RNA: 3 monthsPerforming Laboratory
Mayo Clinic Laboratories in Rochester
CPT Code Information
81456
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| MCRSP | MayoComplete Targeted RNAseq Panel | 95123-6 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 623361 | Result | 82939-0 |
| 623362 | Interpretation | 69047-9 |
| 623363 | Additional Information | 48767-8 |
| 623364 | Specimen | 31208-2 |
| 623365 | Tissue ID | 80398-1 |
| 623366 | Method | 85069-3 |
| 623367 | Disclaimer | 62364-5 |
| 623368 | Released By | 18771-6 |